Published in Yale J Biol Med on December 23, 2016
Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward. Int J Mol Sci (2017) 0.75
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell (1993) 64.62
Translating the histone code. Science (2001) 56.77
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature (2010) 23.55
Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol (2009) 19.99
Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature (2000) 19.15
Histone acetylation in chromatin structure and transcription. Nature (1997) 14.64
DNA methylation and human disease. Nat Rev Genet (2005) 12.00
MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A (2007) 9.82
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Epigenetics in cancer. Carcinogenesis (2009) 7.49
Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol (2014) 7.41
Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res (2014) 7.15
SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer (2011) 6.87
Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res (2011) 6.02
Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg (1999) 5.58
The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res (1999) 4.74
Non-coding RNAs: the architects of eukaryotic complexity. EMBO Rep (2001) 4.74
Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol Cell (2008) 4.44
HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene (2012) 4.30
Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell (2010) 4.18
Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci U S A (2007) 4.04
Whole genomes redefine the mutational landscape of pancreatic cancer. Nature (2015) 4.01
Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene (2008) 3.92
High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci U S A (2004) 3.75
The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis. Annu Rev Biochem (2012) 3.61
The epigenotype. 1942. Int J Epidemiol (2011) 3.52
Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA (2013) 3.46
The reality of pervasive transcription. PLoS Biol (2011) 3.41
Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II. Mol Cell Biol (2009) 3.26
Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res (1997) 3.17
Chromatin regulation by Brg1 underlies heart muscle development and disease. Nature (2010) 2.85
Mutations truncating the EP300 acetylase in human cancers. Nat Genet (2000) 2.84
Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell (2010) 2.80
Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila) (2011) 2.77
Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology (2012) 2.74
mSin3A/histone deacetylase 2- and PRMT5-containing Brg1 complex is involved in transcriptional repression of the Myc target gene cad. Mol Cell Biol (2003) 2.72
Genomic analyses identify molecular subtypes of pancreatic cancer. Nature (2016) 2.70
EZH1 and EZH2 cogovern histone H3K27 trimethylation and are essential for hair follicle homeostasis and wound repair. Genes Dev (2011) 2.63
The molecular biology of mixed lineage leukemia. Haematologica (2009) 2.58
Chromatin remodeling by ATP-dependent molecular machines. Bioessays (2003) 2.57
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat Med (2015) 2.41
Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res (2010) 2.39
The c-myc gene is a direct target of mammalian SWI/SNF-related complexes during differentiation-associated cell cycle arrest. Cancer Res (2006) 2.36
E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology (2009) 2.35
Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene (2008) 2.31
Histone modification and the control of heterochromatic gene silencing in Drosophila. Chromosome Res (2006) 2.28
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A (2013) 2.26
Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation. Genes Dev (2013) 2.07
The Heterochromatin Protein 1 family. Genome Biol (2006) 2.05
Histone exchange, chromatin structure and the regulation of transcription. Nat Rev Mol Cell Biol (2015) 2.02
Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. Cancer Cell (2005) 2.01
Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog (2008) 2.01
Pancreatic cancer. Lancet (2016) 2.01
Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. Clin Gastroenterol Hepatol (2012) 1.99
MicroRNA alterations of pancreatic intraepithelial neoplasias. Clin Cancer Res (2011) 1.97
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun (2015) 1.94
MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer. Br J Cancer (2012) 1.90
The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma. Nat Cell Biol (2014) 1.87
Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol (2008) 1.87
Candidate microRNA biomarkers of pancreatic ductal adenocarcinoma: meta-analysis, experimental validation and clinical significance. J Exp Clin Cancer Res (2013) 1.82
Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res (2011) 1.80
Next-generation sequencing reveals novel differentially regulated mRNAs, lncRNAs, miRNAs, sdRNAs and a piRNA in pancreatic cancer. Mol Cancer (2015) 1.75
DNA methylation in development and human disease. Mutat Res (2008) 1.74
Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol (2015) 1.70
Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer (2005) 1.62
Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. Oncogene (2013) 1.59
DNA methyltransferases, DNA damage repair, and cancer. Adv Exp Med Biol (2013) 1.57
CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS One (2009) 1.52
Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma. Clin Cancer Res (2011) 1.52
A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs (2011) 1.49
miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor. Biochem Biophys Res Commun (2011) 1.42
DNA methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas. Carcinogenesis (2006) 1.42
Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin Cancer Res (2008) 1.39
Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development. Carcinogenesis (2011) 1.38
The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis. Clin Chem (2010) 1.37
Targeting histone modifications--epigenetics in cancer. Curr Opin Cell Biol (2013) 1.36
MLL2, the second human homolog of the Drosophila trithorax gene, maps to 19q13.1 and is amplified in solid tumor cell lines. Oncogene (1999) 1.35
The MLL3/MLL4 branches of the COMPASS family function as major histone H3K4 monomethylases at enhancers. Mol Cell Biol (2013) 1.35
Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun (2015) 1.33
lncRNAs and microRNAs with a role in cancer development. Biochim Biophys Acta (2015) 1.32
Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology (2010) 1.31
c-MYC activation in primary and metastatic ductal adenocarcinoma of the pancreas: incidence, mechanisms, and clinical significance. Mod Pathol (2002) 1.31
miR-148b functions as a tumor suppressor in pancreatic cancer by targeting AMPKα1. Mol Cancer Ther (2012) 1.29
Characterizing DNA methylation patterns in pancreatic cancer genome. Mol Oncol (2009) 1.29
EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors. Nature (2015) 1.28
Molecular biology: RNA discrimination. Nature (2012) 1.28
Transcriptional regulation of the human DNA Methyltransferase (dnmt1) gene. Gene (2000) 1.28
Mll2 is required for H3K4 trimethylation on bivalent promoters in embryonic stem cells, whereas Mll1 is redundant. Development (2014) 1.27
Quantitative dissection and stoichiometry determination of the human SET1/MLL histone methyltransferase complexes. Mol Cell Biol (2013) 1.27
Increased DNA methyltransferase 1 (DNMT1) protein expression in precancerous conditions and ductal carcinomas of the pancreas. Cancer Sci (2005) 1.25
Changing incidence of pancreatic neoplasms: a 16-year review of statewide tumor registry. Pancreas (2008) 1.24
Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. Int J Cancer (2014) 1.24
The epigenetic regulators Bmi1 and Ring1B are differentially regulated in pancreatitis and pancreatic ductal adenocarcinoma. J Pathol (2009) 1.22
Menin: a scaffold protein that controls gene expression and cell signaling. Trends Biochem Sci (2013) 1.21
Epigenetic plasticity: a central regulator of epithelial-to-mesenchymal transition in cancer. Oncotarget (2014) 1.19
Epigenetic alteration and microRNA dysregulation in cancer. Front Genet (2013) 1.19
Polycomb genes and cancer: time for clinical application? Crit Rev Oncol Hematol (2011) 1.19
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Eur J Cancer (2014) 1.17
CpG island methylation profile of pancreatic intraepithelial neoplasia. Mod Pathol (2007) 1.16